| Catalog No. | SF921016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Biosynthetic Parathyroid hormone (PTH) analogs. |
|---|
| Species | Human |
|---|
| Target | Parathyroid hormone, Parathormone, PTH, Parathyrin |
|---|
| Endotoxin level | Please contact with the lab for this information. |
|---|
| Purity | >95% as determined by HPLC. |
|---|
| Purification | Purified by HPLC. |
|---|
| Accession | P01270 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Alternate Names | CAS: 52232-67-4 |
|---|
| Background | Teriparatide is a portion of human parathyroid hormone (PTH), amino acid sequence 1 through 34, of the complete molecule (containing 84 amino acids). Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. PTH increases serum calcium, partially accomplishing this by increasing bone resorption. Thus, chronically elevated PTH will deplete bone stores. However, intermittent exposure to PTH will activate osteoblasts more than osteoclasts. Thus, once-daily injections of teriparatide have a net effect of stimulating new bone formation leading to increased bone mineral density. |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
